Tickers

1. Composite Trajectory Verdict

Given COO's business model as a global medical device company with two distinct segments (contact lenses and fertility/women's health), all three financial statements carry roughly equal weight: the income statement reveals segment profitability and the impact of discrete items, the cash flow statement shows the ability to fund operations, acquisitions, and shareholder returns, and the balance sheet reflects leverage, liquidity, and the growing litigation liability.

Composite Trajectory: Mixed

The composite assessment is Mixed because cash generation is clearly improving (operating cash flow grew 12% in FY2025 and 43% in the first nine months of FY2026), while earnings are mixed (FY2025 operating income and EPS declined versus FY2024, but Q3 FY2026 operating income rose 26% year-over-year, albeit with a $307.2M discrete tax benefit) and the balance sheet shows offsetting forces (total debt roughly stable but working capital collapsed 58% to $414.9M at July 31, 2026 from $993.6M at October 31, 2025 due to a surge in short-term debt and a $316.5M litigation accrual).

2. Red Flags

• Large and growing litigation liability: CooperSurgical recorded a $325.8M accrual (partially offset by $53.8M insurance recoveries) in the first nine months of FY2026 related to the LifeGlobal embryo culture media recall, with $306.8M paid in settlements in August 2026 (10-Q Q3 FY2026, MD&A Contingencies).
• Working capital deterioration: Working capital fell to $414.9M at July 31, 2026 from $993.6M at October 31, 2025, driven by a $580.3M increase in short-term debt (to $628.1M from $47.8M) and the $316.5M litigation accrual (10-Q Q3 FY2026, MD&A Capital Resources and Liquidity; Balance Sheet).
• Short-term debt spike: Short-term debt increased 13-fold to $628.1M at July 31, 2026 from $47.8M at October 31, 2025, primarily due to the $550M term loan tranche maturing December 17, 2026 being reclassified as current (10-Q Q3 FY2026, Balance Sheet; Note 4 Financing Arrangements).
• Discrete tax benefit masking earnings: Q3 FY2026 net income of $432.8M included a $307.2M income tax benefit from the release of an uncertain tax position, while pre-tax income rose only 33% (10-Q Q3 FY2026, MD&A Provision for Income Taxes; Statement of Operations).
• CooperSurgical operating loss in 9M FY2026: Segment operating loss of $157.1M for the nine months ended July 31, 2026 versus $39.7M operating income in the prior year, driven by the $272.0M net litigation expense (10-Q Q3 FY2026, MD&A Operating Income).
• FY2025 margin compression: Consolidated gross margin fell to 66% in FY2025 from 67% in FY2024, and operating margin fell to 17% from 18%, due to inventory/long-lived asset write-offs and severance costs (10-K FY2025, MD&A Gross Margin and Operating Income).
• Accelerated share repurchases amid litigation and debt maturity: The company repurchased $444.7M of stock in the first nine months of FY2026 (versus $92.8M in the prior year) while facing a large near-term debt maturity and litigation payments (10-Q Q3 FY2026, MD&A Share Repurchase; 10-K FY2025, MD&A Share Repurchase).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Overall Assessment: Consolidated net sales grew 5% in FY2025 to $4,092.4M (10-K FY2025, Statement of Operations) and 4.8% in the first nine months of FY2026 to $3,171.8M (10-Q Q3 FY2026, Statement of Operations). However, FY2025 operating income declined 3% to $682.9M (10-K FY2025, Statement of Operations) and diluted EPS fell to $1.87 from $1.96 (10-K FY2025, Statement of Operations). In the first nine months of FY2026, operating income dropped 26% to $403.8M due to a $272.0M litigation charge in CooperSurgical (10-Q Q3 FY2026, MD&A Operating Income). Q3 FY2026 operating income rose 26% to $222.0M year-over-year (10-Q Q3 FY2026, MD&A Operating Income), but net income of $432.8M was inflated by a $307.2M discrete tax benefit (10-Q Q3 FY2026, MD&A Provision for Income Taxes). CooperVision operating income grew consistently (FY2025 +8% to $729.6M; 9M FY2026 +10% to $631.3M), while CooperSurgical swung to a loss in 9M FY2026 (10-K FY2025, Segment Information; 10-Q Q3 FY2026, MD&A Operating Income).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Overall Assessment: Operating cash flow has increased in each of the last three fiscal years: $607.5M in FY2023, $709.3M in FY2024, and $796.1M in FY2025 (10-K FY2025, Statement of Cash Flows). In the first nine months of FY2026, operating cash flow rose 43% to $785.4M from $548.2M in the prior year period, driven by higher net income after adjusting for the non-cash tax benefit and the litigation accrual (10-Q Q3 FY2026, MD&A Capital Resources and Liquidity). Investing cash outflows decreased to $372.9M in FY2025 from $764.6M in FY2024 due to lower acquisition spending (10-K FY2025, Statement of Cash Flows), and to $262.7M in 9M FY2026 from $274.1M in 9M FY2025 (10-Q Q3 FY2026, Statement of Cash Flows). Financing cash flows turned negative in FY2025 (-$425.9M) and 9M FY2026 (-$476.6M) primarily due to share repurchases of $290.1M and $444.7M respectively (10-K FY2025, Statement of Cash Flows; 10-Q Q3 FY2026, Statement of Cash Flows). Free cash flow (operating cash flow less capital expenditures) improved in FY2025 to approximately $433.7M ($796.1M - $362.4M capex) from $288.1M in FY2024 (10-K FY2025, Statement of Cash Flows and Segment Information).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Overall Assessment: Total assets grew modestly to $12,673.4M at July 31, 2026 from $12,394.8M at October 31, 2025 (10-Q Q3 FY2026, Balance Sheet; 10-K FY2025, Balance Sheet). Total debt was roughly flat at $2,544.2M versus $2,505.3M (10-Q Q3 FY2026, Balance Sheet; 10-K FY2025, Note 5). However, the composition shifted dramatically: short-term debt surged to $628.1M from $47.8M as the $550M term loan tranche maturing December 2026 was reclassified (10-Q Q3 FY2026, Balance Sheet; Note 4). Long-term debt fell to $1,916.1M from $2,457.5M due to that reclassification and a $950M tranche extended to 2031 (10-Q Q3 FY2026, Balance Sheet; Note 4). Working capital contracted 58% to $414.9M from $993.6M, driven by the short-term debt increase and a $316.5M current litigation liability (10-Q Q3 FY2026, MD&A Capital Resources and Liquidity; Balance Sheet). Stockholders' equity rose to $8,328.4M from $8,239.1M, supported by retained earnings growth offset by $444.7M of share repurchases in 9M FY2026 (10-Q Q3 FY2026, Balance Sheet; Statement of Cash Flows).

6. Data Gaps

• Quarterly income statement and cash flow data for Q1 and Q2 FY2026 (only Q3 and nine-month aggregates are provided in the 10-Qs).
• Capital expenditures for the nine months ended July 31, 2026 (required to compute free cash flow for that period; the 10-Q investing section does not disaggregate PPE purchases for the nine-month period).
• EBITDA or adjusted EBITDA figures (not disclosed in the provided filings).
• Debt covenant compliance metrics (leverage ratio, interest coverage ratio) in absolute terms (the filings state compliance but do not report the calculated ratios).
• Segment operating income for interim quarters within FY2026 (only nine-month and Q3 figures are provided).
• Full-year FY2026 outlook or guidance (the 10-K covers FY2025; the 10-Qs do not provide annual guidance).